Psych Capital has listed on the Aquis Stock Exchange under the ticker ‘PSY.’
Psych Capital is the first pure play psychedelic healthcare company to list on a UK stock market, marking a major industry milestone as global interest shifts towards Europe due to the proximity of leading research institutions.
The company plans to use the capital raised to develop its existing business and secure further acquisitions.
READ MORE
The state is set to become the first Australian jurisdiction to decriminalise small amounts of psychedelic medicine.
Read More
Synthetic drug production continues to rise on the continent – with 52 new psychoactive substances reported last year.
Read MoreAwakn Life Sciences reports Q1 2022 financial results.
Small Pharma publishes end of fiscal year review.
Tryp release data from Phase II clinical trial.
The path to regulated and accessible psilocybin-assisted therapy
Psychedelic medicine in palliative care.
Mindset receives patent for psilocin derivatives.
Nirvana Life Sciences files psilocybin extraction patent.
Filament Health and Jaguar Health sign drug development LOI.
Beckley Psytech partners with Ksana Health on clinical trial technology.
Natural language signatures of psilocybin microdosing.
Woke Pharmaceuticals and University of Western Australia partner on LSD analogues.
Nova Mentis signs research agreement with University of Central Florida.
Decriminalisation measure stalls in Amherst, Massachusetts.
US House of Representatives pass bill on novel drug follow-up studies.